| Sep 25 |
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
|
| Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
| Sep 12 |
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
|
| Aug 28 |
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
|
| Aug 12 |
Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M
|
| Aug 12 |
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 12 |
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 22 |
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
|
| Jun 21 |
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
|
| Jun 11 |
Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock
|
